01- TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors? In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Read also HERE 02-...
Inst. Coraçao D. Eugenio Araujo Sales_VOTI-COR Location: E-mail: joc4@uol.com.br
Sanatorio Mitre Location: E-mail: apalacios@fibertel.com.ar
Hospital General de Culiacan Sinaola Location: E-mail: octaviobeltran@gmail.com
✔️ Watch again the Edwards Lifesciences Symposium in the SOLACI-CACI 2021 Virtual Congress.✔️ Topic: Overcoming Challenges of the BALLOON EXPANDABLE TAVI Cases. 👨🏫 Program: 00:05 – Opening – Dr. José Mangione (BRA). 02:20 – Aortic VinV in small annuli: Does the final gradient matter? – Dr. Adolfo Ferrero (ARG). 21:14 – Small Annuli and...
The enthusiasm for direct oral anticoagulants after transcatheter aortic valve replacements (TAVR) is waning. At least, when it combines with atrial fibrillation. The ENVISAGE-TAVI AF has shown excessive bleeding with endoxaban vs. the classical vitamin K antagonists. Endoxaban resulted non-inferior to vitamin K antagonists in terms of net clinical adverse events, but major bleeding events...
Aspirin monotherapy (ASA) reduced the combined risk of thrombotic and bleeding events compared against dual antiplatelet therapy (DAPT) in patients receiving transcatheter aortic valve replacement (TAVR). This meta-analysis has only reproduced smaller randomize study outcomes and does not include the OCEAN-TAVI registry, the only one that has shown something different so far. Even though ASA...
